# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-23T07:37:19.482893

---

**Idea Fidelity**

The submitted draft deviates from the documented idea manifest in important ways. The manifest envisioned using T-MSIS claims data to assess whether SNAP-mediated ex parte renewals stabilized provider utilization, exploiting normalized claims trajectories and secondary outcomes such as behavioral health claims. Instead, the paper analyzes CMS monthly Medicaid/CHIP enrollment only, and the main results come from dynamics around state-level enrollment retention. While both narratives share the policy context (the 2023–24 unwinding) and the notion that SNAP data coordination can serve as an administrative buffer, the empirical focus has shifted to a different outcome and a different operationalization of treatment (17 e14-waiver states only, rather than the 26-state coordination universe). This matters because the paper no longer speaks to health care delivery consequences via claims, nor does it exploit the rich provider-side data the manifest emphasized. If the authors intend to pivot to the enrollment question, the manuscript should explicitly acknowledge the divergence and clarify why the original claims-based strategy was abandoned. Otherwise, the paper risks being judged a partial realization of the original idea.

---

**Summary**

The paper studies whether states that received Section 1902(e)(14)(A) waivers to use SNAP records for ex parte Medicaid renewals experienced smaller enrollment declines during the 2023–24 unwinding. Using a two-way fixed effects DiD with state and month fixed effects, the pooled treatment effect is statistically indistinguishable from zero. However, an event study suggests a delayed benefit: little difference in the early months post-unwinding, followed by a growing advantage (5–6.5 percentage points of baseline enrollment) in months six through twelve, which the authors interpret as the SNAP buffer offsetting procedural disenrollment as administrative burdens accumulated.

---

**Essential Points**

1. **Parallel Trends Assumption Compromised:** The event study table reveals a statistically significant positive difference between treated and control states well before the treatment (e.g., +2.6 pp at month -12, +0.9 pp at -9, +0.5 pp at -6). These pre-treatment coefficients are not only statistically significant but economically material, which undermines the maintained assumption that treatment and control would have followed parallel enrollment paths absent the waivers. Given the lack of staggered timing, there is no credible source of identification beyond this assumption. The authors must either better justify why the pre-trends are acceptable (e.g., by showing they are due to measurement noise or compositional changes that do not affect the post period) or adopt alternative strategies (matching, synthetic controls, or triple differences) that do not rely on pre-trends holding.

2. **Event Study Interpretation Contradicts Statistical Precision:** The event study estimates post-treatment have wide confidence intervals that consistently include zero (e.g., month 6 coefficient 0.0247, SE 0.0198; month 9 coefficient 0.0179, SE 0.0217). The assertion that the SNAP buffer “grows to 5–6.5 percentage points” is not supported by these precision levels; indeed, the pooled estimate is 0.95 pp with $p=0.62$. Without statistically distinguishable effects in the post period, claims about meaningful impacts are premature. The authors should present measures of statistical uncertainty alongside the dynamic story and consider whether the strong interpretation can be sustained; if not, they should temper the claims or seek stronger identification (e.g., leveraging heterogeneity where standard errors shrink).

3. **Remaining Confounders and Mechanism Validation:** States that obtained E14 waivers are likely those with greater administrative capacity, stronger safety-net coordination, or more aggressive unwinding strategies (e.g., better outreach, additional pauses). These factors could independently influence enrollment trajectories. The paper currently tests a placebo on disenrollment pauses, but the substantive concern is that waiver status is correlated with unobserved time-varying policies (e.g., supplemental outreach, different redetermination timing) that also affect enrollment. Without controlling for these contemporaneous efforts or alternatively instrumenting for waiver status, the estimated “SNAP buffer” may capture broader state-level administrative quality. The authors should incorporate, at a minimum, controls for other redetermination policies (pauses, staffing, outreach intensity) and ideally show that the effect persists within more comparable subsets (e.g., matching states on pre-2023 renewal processes).

If the authors cannot adequately address these essential concerns, particularly the invalid pre-trends and the lack of statistically significant post-period effects, the paper should not be published in its current form.

---

**Suggestions**

1. **Reconcile with Manifest and Broaden Outcomes:** If the original focus on T-MSIS claims was impractical, explicitly say so in the introduction and discuss the implications of the pivot to enrollment. If claim data are available, consider integrating them to align with the “health care delivery consequences” angle. At a minimum, explain why claims were dropped (data access issues? insufficient variation?) and what is lost/gained by analyzing enrollment instead.

2. **Improve Pre-Trend Diagnostics and Identification Strategy:** Given the significant pre-treatment differences, re-estimate the event study with leads expressed as normalized differences that account for seasonality (perhaps using monthly fixed effects for each state’s enrollment growth trend). If the early differences reflect levels rather than trends, consider demeaning the outcome or using first differences to control for nonparallel but stable divergences. Alternatively, try a synthetic control for each treated state or a stacked DiD using nearest-neighbor matched controls to see if the delayed effect remains when treated states are compared to more similar peers.

3. **Strengthen Mechanism Evidence:** The delayed onset narrative is plausible, but the paper lacks empirical backing for the backlog/queue explanation. Introduce additional evidence: e.g., compare the share of renewals processed ex parte over time (if available) or show that the divergence correlates with SNAP-Medicaid dual participation shares. If microdata are unavailable, supplement with descriptive statistics showing that the treated states have higher SNAP overlap and that the timing of SNAP recertification peaks around months six through twelve, consistent with the proposed mechanism. Alternatively, use Medicaid disenrollment categories (if accessible) to show fewer procedural terminations in waiver states post-month four.

4. **Quantify Exposure Using SNAP-Medicaid Overlap:** The benefit of SNAP data coordination should depend on the proportion of Medicaid enrollees also on SNAP. Incorporating a dose-response analysis—interacting waiver status with pre-unwinding SNAP share—would provide face validity and could sharpen estimates by exploiting within-treatment variation. This could also help address concerns about selection: even among waiver states, those with low SNAP overlap should exhibit smaller effects, which would bolster the causal story.

5. **Report Post-Estimation Diagnostics and Robustness:** Present the event study with confidence intervals (maybe in figure form) rather than only point estimates. Also, show placebo tests on other outcomes (e.g., CHIP enrollment, or a lead period after 2022) to demonstrate that the dynamic pattern is specific to the unwinding. Explore whether results change when excluding large states (CA, NY) whose enrollment dynamics dominate the aggregate, or when weighting states equally rather than by population.

6. **Consider Alternative Outcomes Beyond Enrollment:** To capture “resilience” more precisely, examine other publicly available indicators aligned with claims (if T-MSIS access is infeasible). For instance, did waiver states have smaller declines in managed care payments or provider encounters reported in CMS enrollment supplements? Another possibility is to use ACS or survey data on insurance coverage, though these are less granular in time.

7. **Clarify Policy Implications with Realistic Cost-Benefit Framing:** The claim that building cross-program data infrastructure is “cheap relative to coverage preserved” is compelling but needs numerical context. Provide back-of-the-envelope estimates of the costs of implementing SNAP data coordination (perhaps citing CMS modernization budgets) and compare them to the estimated enrollment gains (even if noisy). This helps policymakers gauge the trade-offs more concretely.

8. **Address Limitations More Directly:** The paper notes that auto-renewals might prolong coverage for ineligible individuals; consider exploring this possibility by looking at subsequent enrollment churn or Medicaid spending per beneficiary in waiver states. If data are unavailable, mention more explicitly how this concern tempers the conclusions and what future work could do (e.g., audit sampling of renewal accuracy).

9. **Provide More Transparent Code/Data Workflow:** Since the authors reference massive datasets (e.g., 227M rows T-MSIS), briefly describe the data processing steps. In an empirical short paper, a short appendix with variable construction, data sources (with URLs), and repository links would increase transparency and reproducibility.

In sum, the paper addresses an important policy question, but it currently lacks a credible identification strategy and the claimed effects are not statistically supported. Strengthening the pre-trend diagnostics, incorporating dose-response or matched comparisons, and aligning the empirical focus with the original idea (or justifying the pivot) would substantially improve the manuscript.
